Plow­ing ahead af­ter its lat­est set­back, Ax­o­vant nabs two as­sets to beef up gene ther­a­py pipeline

Fresh from the spec­tac­u­lar fail­ure of its de­men­tia drug, nelotanserin, which has been pushed to the scrap heap along with its much-hyped Alzheimer’s as­set, Ax­o­vant $AX­ON is mov­ing on fast at the be­hest of its deal hun­gry pa­tron Vivek Ra­maswamy.

On Thurs­day, the com­pa­ny said it had struck a deal to li­cense the glob­al rights to de­vel­op and mar­ket two gene ther­a­py pro­grams de­signed to ad­dress two pro­gres­sive and fa­tal pe­di­atric lyso­so­mal stor­age dis­or­ders: GM1 gan­gliosi­do­sis and GM2 gan­gliosi­do­sis – al­so known as Tay-Sachs and Sand­hoff dis­eases – from the Uni­ver­si­ty of Mass­a­chu­setts Med­ical School.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER